Mode
Text Size
Log in / Sign up
N/A N=281

Examining Racial and SocioEconomic Disparities (ERASED) in Chronic Low Back Pain Study

Back Pain Lower Back Chronic

Enrolled (actual)
281
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: Average Clinical Pain Severity — 5.1; 3.9 units on a scale

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
QST (Other)
Age
Adult, Older Adult · 19+ yrs
Sex
All
Sponsor
University of Alabama at Birmingham
Primary completion
Jan 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Average Clinical Pain Severity
5.1; 3.9
SECONDARY
Average Pain Threshold (Heat)
39.96; 40.54
SECONDARY
Average Pain Tolerance (Heat)
42.50; 44.61
SECONDARY
Difference in Temporal Summation of Pain (Mechanical)
20.16; 12.68
SECONDARY
Difference in Pressure Pain Thresholds Assessed Using Conditioned Pain Modulation
-7.82; -10.80
SECONDARY
Total Level of C-reactive Protein
6394.52; 5040.71
SECONDARY
Total Level of Fibrinogen
1656.55; 1417.26
SECONDARY
Total Level of Serum Amyloid A
12224.88; 9109.35
SECONDARY
Total Level of Vitamin D
20.5; 26.9
SECONDARY
Total Level of Oxytocin
181.54; 192.71
SECONDARY
Sleep Quality
12.08; 12.12
SECONDARY
Self-reported Disability
53.40; 41.96
SECONDARY
Evoked Pain With Movement
31.01; 13.33
SECONDARY
Functional Performance
8.95; 9.82

Summary

It remains unclear whether certain disadvantaged subgroups of society may be at heightened risk for poor chronic low back pain (cLBP) outcomes. The overall aim of this study is to incorporate a socioeconomic framework to characterize racial differences in cLBP severity and disability. Further, guided by the theory of fundamental causes, we aim to examine racial and socioeconomic status differences in biopsychosocial predictors of cLBP outcomes, particularly endogenous pain modulation.

Eligibility Criteria

Inclusion Criteria

  • Chronic low back pain that has been going on consistently for the last 6 months.

Exclusion Criteria

  • Surgery (fusion, Laminectomy) in the last year, accident or trauma in the last year, uncontrolled high blood pressure, heart disease, cancer, diabetes HbA1c > 7%, Ankylosing Spondylitis, Infection, Parkinson's Disease, Multiple Sclerosis, Epilepsy, Stroke, Seizure (non-epileptic), Systemic Lupus Erythematosus, Fibromyalgia, Raynaud's disease, Major Depression/Bipolar Disorder, HIV
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03338192). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search